Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

Kidney: Renal cell carcinomas with MiT family translocation

Written2016-08Pedram Argani
Department of Pathology, The Johns Hopkins Hospital, Baltimore MD (PA) pargani@jhmi.edu

(Note : for Links provided by Atlas : click)

Abstract

Abstract Review on Renal cell carcinomas with MiT family translocations, with data on clinics, and the genes involved.

Identity

ICD-Topo C649 Kidney
Atlas_Id 5118
Phylum Urinary system: Kidney::Renal cell carcinoma

Clinics and Pathology

Disease Xp11 translocation renal cell carcinomas (RCCs) harbor gene fusions involving TFE3 transcription factor. The t(6;11) RCCs harbor a specific MALAT1 (Alpha)-TFEB gene fusion. TFEB and TFE3 belong to the same MiT subfamily of transcription factors (MiT for microphthalmia-TFE). Because of similarities at the clinical, morphologic, immunohistochemical, and genetic levels, the Xp11 translocation RCCs and t(6;11) RCCs are currently grouped together under the category of MiT family translocation renal cell carcinoma.
Epidemiology Xp11 translocation RCC are the most common RCC in children, and comprises approximately 1% of adult RCC. There are only approximately 50 reported cases of t(6;11) RCC, median age is 31 years. Both RCC have been associated with prior exposure to cytotoxic chemotherapy.
Clinics These form masses in the kidney. Xp11 translocation RCC are frequently calcified on imaging.
Pathology Xp11 translocation RCC most commonly feature papillary architecture and epithelioid clear cells, with abundant psammoma bodies. Xp11 translocation RCCs can also present with unusual morphology mimicking other types of RCCs. Xp11 translocation RCCs can show solid or nested growth with clear to granular eosinophilic cytoplasm mimicking clear cell RCC, multilocular cystic RCC-like features, anaplastic/pleomorphic giant cells, tubular growth reminiscent of collecting duct carcinoma, well-developed fascicles of spindled neoplastic cells with bland nuclei in focal myxoid stroma mimicking mucinous tubular and spindle cell carcinoma, sarcomatoid change, oncocytic areas mimicking oncocytoma, oncocytic spindled areas resembling epithelioid angiomyolipoma, trabecular patterns mimicking carcinoid tumor, and colonization of renal pelvic urothelium mimicking urothelial carcinoma.
The t(6;11) RCC typically demonstrates a distinctive biphasic morphology, comprising larger epithelioid cells and small cells clustered around basement membrane material. The larger epithelioid cells may have clear to eosinophilic cytoplasm, and their nested architecture is similar to that of clear cell RCC. The smaller cells clustered around basement membrane material resemble the Call-Exner bodies of adult granulosa cell tumor. These neoplasms typically do not show prominent cytologic atypia or mitotic activity. While these lesions appear well delineated grossly, microscopically they characteristically entrap single native renal tubules at their periphery. Over time and with greater experience a broad range of morphologic appearances have been found in the t(6;11) RCC. Some of the illustrated morphologic appearances in genetically-confirmed cases include extensive hyalinization (both nodular mass-forming hyalinization and diffuse pericellular hyalinization), papillary architecture mimicking papillary RCC, clear cell morphology with an absence of smaller cells mimicking clear cell RCC, oncocytoma like morphology, oncocytic papillary morphology, cystic dilatation of entrapped renal tubules leading to a grossly cystic appearance, tubulocystic carcinoma-like morphology, and higher grade nested architecture which raises the broad differential diagnosis of high grade unclassified RCC.
Treatment Surgical excision.

Cytogenetics

Cytogenetics
Morphological
Table 1. TFE3 or TFEB Gene Fusions

Neoplasm

Fusion

Age Range (years)

Translocation

ASPS

ASPSCR1/TFE3

1-71

der(17)(X;17)(p11.2q25)

RCC

ASPSCR1/TFE3

1-75

t(X;17)(p11.2;q25)

RCC

PRCC/TFE3

2-69

t(X;1)(p11.2;q21)

RCC

SFPQ/TFE3

3-68

t(X;1)(p11.2;p34)

RCC

NONO/TFE3

29-51

inv(X)(p11.2q12)

RCC

CLTC/TFE3

14

t(X;17)(p11.2;q23)

RCC

PARP14/TFE3

32

t(X;3)(p11.2;q23)

RCC

DVL2/TFE3

73

t(X;17)(p11;p13)

RCC

LUC7L3/TFE3

 

t(X;17)(p11;q21)

RCC

RBM10/TFE3

32

inv(X)(p11.2p11.23)

RCC

KHSRP/TFE3

 

t(X;19)(p11.2;p13)

Xp11 PEComa

SFPQ/TFE3, NONO/TFE3 and others

9-55

t(X;1)(p11.2;p34), inv(X)(p11.2q12) and others

Melanotic Xp11 Translocation Cancer

SFPQ/TFE3 and likely others

11-55

t(X;1)(p11.2;q34) and likely others

Subset of Epithelioid Hemangioendothelioma

YAP1/TFE3

14-50

t(X;11)(p11.2;q13)

RCC

MALAT1(Alpha)-TFEB

3-68

t(6;11)(p21;q12)

RCC

CLTC/TFEB

 

t(6;17)(p21;q23)

RCC

KHDRBS2/TFEB

 

inv(6)(p21q11)

RCC

COL21/TFEB

 

inv(6)(p21p12)

RCC

TFEB/CADM2

 

t(3;6)(p12;p21)


ASPS= Alveolar soft part sarcoma
RCC= Renal cell carcinoma
PEComa= Perivascular epithelioid cell tumor

Result of the chromosomal anomaly

Fusion Protein
Description Xp11 translocation renal cell carcinomas (RCCs) demonstrate fusion of the TFE3 transcription factor gene with one of multiple reported genes including ASPSCR1 (ASPL), PRCC, NONO (p54nrb), SFPQ (PSF), and, lastly, CLTCin the t(X;17)(p11.2;q23) Table 1). The two most common Xp11 translocation RCCs are those bearing the t(X;1)(p11.2;q21) which fuses the PRCC and TFE3 genes and the t(X;17)(p11.2;q25)which fuses the ASPSCR1 and TFE3 genes. The ASPSCR1/TFE3 gene fusion is the same gene fusion found in alveolar soft part sarcoma (ASPS), a rare pediatric neoplasm of uncertain histogenesis. Other common translocations are the inv (X)(p11.2q12) which fuses the NONO (p54nrb) and TFE3 genes; the t(X;1)(p11.2;p34) which fuses the SFPQ (PSF) and TFE3 genes. Although native TFE3 transcription factor protein is ubiquitously expressed, its normal levels are generally undetectable by immunohistochemistry. However, the TFE3 gene fusion partners in the Xp11 translocation RCC contribute strong promoters leading to overexpression of the fusion protein and strong nuclear labeling for TFE3 by immunohistochemistry.
The t(6;11)(p21;q12) translocation fuses the gene for transcription factor EB ( TFEB) with MALAT1 (Alpha), an untranslated gene of unknown function, resulting in overexpression of native TFEB. Along these lines, the t(6;11) RCCs (also known as Alpha-TFEB RCCs) demonstrate specific nuclear labeling for TFEB protein by immunohistochemistry, whereas TFEB protein is not detected by immunohistochemistry in other neoplasms and normal tissues.
  

Bibliography

A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21
Argani P, Hawkins A, Griffin CA, Goldstein JD, Haas M, Beckwith JB, Mankinen CB, Perlman EJ
1;q12) chromosome translocation Am J Pathol
PMID 11395386
 
Translocation carcinomas of the kidney after chemotherapy in childhood
Argani P, Laé M, Ballard ET, Amin M, Manivel C, Hutchinson B, Reuter VE, Ladanyi M
J Clin Oncol 2006 Apr 1;24(10):1529-34
PMID 16575003
 
Molecular confirmation of t(6;11)(p21;q12) renal cell carcinoma in archival paraffin-embedded material using a break-apart TFEB FISH assay expands its clinicopathologic spectrum
Argani P, Yonescu R, Morsberger L, Morris K, Netto GJ, Smith N, Gonzalez N, Illei PB, Ladanyi M, Griffin CA
Am J Surg Pathol 2012 Oct;36(10):1516-26
PMID 22892601
 
t(6;11) renal cell carcinoma (RCC): expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases
Smith NE, Illei PB, Allaf M, Gonzalez N, Morris K, Hicks J, Demarzo A, Reuter VE, Amin MB, Epstein JI, Netto GJ, Argani P
Am J Surg Pathol 2014 May;38(5):604-14
PMID 24618616
 
Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR
Argani P, Laé M, Hutchinson B, Reuter VE, Collins MH, Perentesis J, Tomaszewski JE, Brooks JS, Acs G, Bridge JA, Vargas SO, Davis IJ, Fisher DE, Ladanyi M
Am J Surg Pathol 2005 Feb;29(2):230-40
PMID 15644781
 
Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents
Argani P, Antonescu CR, Illei PB, Lui MY, Timmons CF, Newbury R, Reuter VE, Garvin AJ, Perez-Atayde AR, Fletcher JA, Beckwith JB, Bridge JA, Ladanyi M
Am J Pathol 2001 Jul;159(1):179-92
PMID 11438465
 
Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage
Ellis CL, Eble JN, Subhawong AP, Martignoni G, Zhong M, Ladanyi M, Epstein JI, Netto GJ, Argani P
Mod Pathol 2014 Jun;27(6):875-86
PMID 24309327
 
Translocation carcinomas of the kidney after chemotherapy in childhood
Argani P, Laé M, Ballard ET, Amin M, Manivel C, Hutchinson B, Reuter VE, Ladanyi M
J Clin Oncol 2006 Apr 1;24(10):1529-34
PMID 16575003
 
PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11
Argani P, Antonescu CR, Couturier J, Fournet JC, Sciot R, Debiec-Rychter M, Hutchinson B, Reuter VE, Boccon-Gibod L, Timmons C, Hafez N, Ladanyi M
2;q21) Am J Surg Pathol
PMID 12459622
 
Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service
Green WM, Yonescu R, Morsberger L, Morris K, Netto GJ, Epstein JI, Illei PB, Allaf M, Ladanyi M, Griffin CA, Argani P
Am J Surg Pathol 2013 Aug;37(8):1150-63
PMID 23715164
 
Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay
Argani P, Lal P, Hutchinson B, Lui MY, Reuter VE, Ladanyi M
Am J Surg Pathol 2003 Jun;27(6):750-61
PMID 12766578
 
Next-generation sequencing of translocation renal cell carcinoma reveals novel RNA splicing partners and frequent mutations of chromatin-remodeling genes
Malouf GG, Su X, Yao H, Gao J, Xiong L, He Q, Compérat E, Couturier J, Molinié V, Escudier B, Camparo P, Doss DJ, Thompson EJ, Khayat D, Wood CG, Yu W, Teh BT, Weinstein J, Tannir NM
Clin Cancer Res 2014 Aug 1;20(15):4129-40
PMID 24899691
 
Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes
Durinck S, Stawiski EW, Pavía-Jiménez A, Modrusan Z, Kapur P, Jaiswal BS, Zhang N, Toffessi-Tcheuyap V, Nguyen TT, Pahuja KB, Chen YJ, Saleem S, Chaudhuri S, Heldens S, Jackson M, Peña-Llopis S, Guillory J, Toy K, Ha C, Harris CJ, Holloman E, Hill HM, Stinson J, Rivers CS, Janakiraman V, Wang W, Kinch LN, Grishin NV, Haverty PM, Chow B, Gehring JS, Reeder J, Pau G, Wu TD, Margulis V, Lotan Y, Sagalowsky A, Pedrosa I, de Sauvage FJ, Brugarolas J, Seshagiri S
Nat Genet 2015 Jan;47(1):13-21
PMID 25401301
 
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
Cancer Genome Atlas Research Network, Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AA, Shinbrot E, Sethi A, Brooks S, Rathmell WK, Brooks AN, Hoadley KA, Robertson AG, Brooks D, Bowlby R, Sadeghi S, Shen H, Weisenberger DJ, Bootwalla M, Baylin SB, Laird PW, Cherniack AD, Saksena G, Haake S, Li J, Liang H, Lu Y, Mills GB, Akbani R, Leiserson MD, Raphael BJ, Anur P, Bottaro D, Albiges L, Barnabas N, Choueiri TK, Czerniak B, Godwin AK, Hakimi AA, Ho TH, Hsieh J, Ittmann M, Kim WY, Krishnan B, Merino MJ, Mills Shaw KR, Reuter VE, Reznik E, Shelley CS, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Tickoo S, Burnett K, Crain D, Gardner J, Lau K, Mallery D, Morris S, Paulauskis JD, Penny RJ, Shelton C, Shelton WT, Sherman M, Thompson E, Yena P, Avedon MT, Bowen J, Gastier-Foster JM, Gerken M, Leraas KM, Lichtenberg TM, Ramirez NC, Santos T, Wise L, Zmuda E, Demchok JA, Felau I, Hutter CM, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Zhang J, Ayala B, Baboud J, Chudamani S, Liu J, Lolla L, Naresh R, Pihl T, Sun Q, Wan Y, Wu Y, Ally A, Balasundaram M, Balu S, Beroukhim R, Bodenheimer T, Buhay C, Butterfield YS, Carlsen R, Carter SL, Chao H, Chuah E, Clarke A, Covington KR, Dahdouli M, Dewal N, Dhalla N, Doddapaneni HV, Drummond JA, Gabriel SB, Gibbs RA, Guin R, Hale W, Hawes A, Hayes DN, Holt RA, Hoyle AP, Jefferys SR, Jones SJ, Jones CD, Kalra D, Kovar C, Lewis L, Li J, Ma Y, Marra MA, Mayo M, Meng S, Meyerson M, Mieczkowski PA, Moore RA, Morton D, Mose LE, Mungall AJ, Muzny D, Parker JS, Perou CM, Roach J, Schein JE, Schumacher SE, Shi Y, Simons JV, Sipahimalani P, Skelly T, Soloway MG, Sougnez C, Tam A, Tan D, Thiessen N, Veluvolu U, Wang M, Wilkerson MD, Wong T, Wu J, Xi L, Zhou J, Bedford J, Chen F, Fu Y, Gerstein M, Haussler D, Kasaian K, Lai P, Ling S, Radenbaugh A, Van Den Berg D, Weinstein JN, Zhu J, Albert M, Alexopoulou I, Andersen JJ, Auman JT, Bartlett J, Bastacky S, Bergsten J, Blute ML, Boice L, Bollag RJ, Boyd J, Castle E, Chen YB, Cheville JC, Curley E, Davies B, DeVolk A, Dhir R, Dike L, Eckman J, Engel J, Harr J, Hrebinko R, Huang M, Huelsenbeck-Dill L, Iacocca M, Jacobs B, Lobis M, Maranchie JK, McMeekin S, Myers J, Nelson J, Parfitt J, Parwani A, Petrelli N, Rabeno B, Roy S, Salner AL, Slaton J, Stanton M, Thompson RH, Thorne L, Tucker K, Weinberger PM, Winemiller C, Zach LA, Zuna R
N Engl J Med 2016 Jan 14;374(2):135-45
PMID 26536169
 
Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma
Antonescu CR, Le Loarer F, Mosquera JM, Sboner A, Zhang L, Chen CL, Chen HW, Pathan N, Krausz T, Dickson BC, Weinreb I, Rubin MA, Hameed M, Fletcher CD
Genes Chromosomes Cancer 2013 Aug;52(8):775-84
PMID 23737213
 

Citation

This paper should be referenced as such :
Argani P
Kidney: Renal cell carcinomas with MiT family translocatio
Atlas Genet Cytogenet Oncol Haematol. in press
On line version : http://AtlasGeneticsOncology.org/Tumors/RCCMiTtranslocID5118.html


Translocations implicated (Data extracted from papers in the Atlas)

 inv(X)(p11q12) NONO/TFE3
 t(X;1)(p11;p34) SFPQ/TFE3
 t(X;1)(p11;q21) PRCC/TFE3
 t(X;17)(p11;q23) CLTC/TFE3
 t(X;17)(p11;q25) ASPSCR1/TFE3
 t(6;11)(p21;q12) MALAT1/TFEB

External links

Mitelman database inv(X)(p11q12) NONO/TFE3 [Case List]    inv(X)(p11q12) NONO/TFE3 [Association List] Mitelman database (CGAP - NCBI)
Mitelman database t(X;1)(p11;p34) SFPQ/TFE3 [Case List]    t(X;1)(p11;p34) SFPQ/TFE3 [Association List] Mitelman database (CGAP - NCBI)
Mitelman database t(X;1)(p11;q21) PRCC/TFE3 [Case List]    t(X;1)(p11;q21) PRCC/TFE3 [Association List] Mitelman database (CGAP - NCBI)
Mitelman database t(X;17)(p11;q23) CLTC/TFE3 [Case List]    t(X;17)(p11;q23) CLTC/TFE3 [Association List] Mitelman database (CGAP - NCBI)
Mitelman database t(X;17)(p11;q25) ASPSCR1/TFE3 [Case List]    t(X;17)(p11;q25) ASPSCR1/TFE3 [Association List] Mitelman database (CGAP - NCBI)
Mitelman database t(6;11)(p21;q12) MALAT1/TFEB [Case List]    t(6;11)(p21;q12) MALAT1/TFEB [Association List] Mitelman database (CGAP - NCBI)
arrayMap Topo ( C64) arrayMap ((UZH-SIB Zurich)   [auto + random 100 samples .. if exist ]   [tabulated segments]
 
 
Disease databaseKidney: Renal cell carcinomas with MiT family translocation
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Wed May 3 17:28:17 CEST 2017


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.